0000000000660369

AUTHOR

R Mehran

showing 2 related works from this author

Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELT…

2016

AIMS Our aim was to compare, in a large unprotected left main coronary artery (ULMCA) all-comer registry, the long-term clinical outcome after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in patients with acute coronary syndrome (ACS). METHODS AND RESULTS Of a total of 2,775 patients enrolled in the Drug Eluting Stents for Left Main Coronary Artery Disease (DELTA) multicentre registry, 379 (13.7%) patients with ACS treated with PCI (n=272) or CABG (n=107) were analysed. Baseline demographics were considerably different in the two groups before propensity matching. No significant differences emerged for…

AdultMalemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineInternal medicineHumansMedicineRegistriescardiovascular diseases030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeCoronary Artery BypassStrokeAgedAged 80 and overbusiness.industryIncidence (epidemiology)Coronary StenosisPercutaneous coronary interventionDrug-Eluting StentsMiddle Agedmedicine.diseaseSurgeryStrokeTreatment Outcomemedicine.anatomical_structurePropensity score matchingConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessArteryEuroIntervention
researchProduct

Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 ran…

2016

Background Women comprise almost 50% of patients undergoing transcatheter aortic valve replacement (TAVR) and previous studies have indicated higher rates of procedural complications and bleeding in women compared to men. It is unknown whether men and women demonstrate a differential response to bivalirudin versus unfractionated heparin (UFH) in TAVR. We sought to evaluate outcomes by sex and type of anticoagulant from the Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement (BRAVO-3) trial of transfemoral TAVR. Methods BRAVO-3 was a randomized multicenter trial comparing transfemoral TAVR with bivalirudin versus UFH (31 centers, n = 802). The primary endpoin…

Aortic valvemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineValve replacementInternal medicineMulticenter trialmedicineBivalirudinRadiology Nuclear Medicine and imaging030212 general & internal medicinebusiness.industryAnticoagulantEuroSCOREGeneral Medicinemedicine.diseasemedicine.anatomical_structureAortic valve stenosisCardiologyCardiology and Cardiovascular MedicinebusinessMacemedicine.drugCatheterization and Cardiovascular Interventions
researchProduct